Swedencare AB (SE:SECARE)
:SECARE
Want to see SE:SECARE full AI Analyst Report?
Top Page
Swedencare AB
(SECARE)
Select Model
Select Model
Rating:59Neutral
Price Target:
kr28.00
▲(19.91% Upside)
Action:Reiterated
Date:04/24/26
The score is driven primarily by solid top-line growth but constrained by margin compression and weakening cash-flow trends, with only moderate balance-sheet support. Technicals are mildly constructive in the near term, but the longer-term trend remains weak. A very high P/E with a modest dividend yield is the biggest headwind to the overall score.
Positive Factors
Strong revenue growth
TTM revenue growth of +34% suggests persistent demand and product-market fit in companion-animal health. Over a 2–6 month horizon this momentum supports scale benefits, distribution leverage and reinvestment capacity for marketing and product development, underpinning durable sales expansion.
Negative Factors
Margin compression
Significantly compressed margins versus 2024 indicate structural pressure from higher costs or pricing mix shifts. Persistently thin margins will limit free cash flow, constrain reinvestment and magnify sensitivity to cost inflation, making sustainable profitability a key medium-term risk.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong revenue growth
TTM revenue growth of +34% suggests persistent demand and product-market fit in companion-animal health. Over a 2–6 month horizon this momentum supports scale benefits, distribution leverage and reinvestment capacity for marketing and product development, underpinning durable sales expansion.
Read all positive factors
Swedencare AB (SECARE) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr4.22B
Dividend Yield0.66%
Average Volume (3M)305.00K
Price to Earnings (P/E)85.4
Beta (1Y)0.76
Revenue Growth4.60%
EPS Growth-46.98%
CountrySE
Employees587
SectorConsumer Defensive
Sector Strength42
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.31
Shares Outstanding159,840,960
10 Day Avg. Volume222,741
30 Day Avg. Volume305,002
Financial Highlights & Ratios
PEG Ratio-2.54
Price to Book (P/B)0.92
Price to Sales (P/S)2.27
P/FCF Ratio22.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr45.00Price Target Upside92.72% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.43
Revenue Forecast (FY)kr2.89B
Swedencare AB Business Overview & Revenue Model
Company Description
Swedencare AB (publ), an enterprise established in 1993 and headquartered in Malmö, Sweden, operates with its subsidiaries to develop, produce, market, and sell a wide array of healthcare products, predominantly for animals. The company's flagship...
How the Company Makes Money
Swedencare makes money primarily by selling pet health products to business customers and consumers through multiple channels. Key revenue streams include: (1) Product sales to veterinary clinics and veterinary distributors, where Swedencare suppl...
Swedencare AB Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
74
Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.70B | 2.69B | 2.54B | 2.34B | 1.83B | 770.44M |
| Gross Profit | 1.19B | 1.52B | 1.46B | 1.29B | 1.02B | 385.87M |
| EBITDA | 469.80M | 446.00M | 549.50M | 484.00M | 392.40M | 138.73M |
| Net Income | 49.40M | 55.50M | 98.90M | 58.60M | 94.50M | 54.62M |
Balance Sheet | ||||||
| Total Assets | 9.75B | 9.51B | 10.32B | 9.52B | 10.00B | 3.47B |
| Cash, Cash Equivalents and Short-Term Investments | 94.90M | 103.00M | 186.80M | 237.30M | 245.07M | 136.09M |
| Total Debt | 1.76B | 2.10B | 1.51B | 1.66B | 1.91B | 721.53M |
| Total Liabilities | 2.82B | 2.84B | 2.28B | 2.32B | 2.54B | 1.05B |
| Stockholders Equity | 6.93B | 6.66B | 8.03B | 7.21B | 7.46B | 2.42B |
Cash Flow | ||||||
| Free Cash Flow | 244.90M | 275.60M | 287.80M | 408.00M | 185.51M | 98.06M |
| Operating Cash Flow | 295.30M | 326.80M | 359.10M | 444.00M | 260.20M | 125.85M |
| Investing Cash Flow | -507.60M | -531.40M | -151.90M | -176.40M | -4.67B | -1.87B |
| Financing Cash Flow | -214.60M | 137.80M | -274.20M | -271.60M | 4.49B | 1.59B |
Swedencare AB Technical Analysis
Positive
23.35
Price Trends
26.13
Positive
26.41
Positive
31.43
Negative
Market Momentum
0.26
Negative
59.13
Neutral
59.03
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SECARE, the sentiment is Positive. The current price of 23.35 is below the 20-day moving average (MA) of 26.28, below the 50-day MA of 26.13, and below the 200-day MA of 31.43, indicating a neutral trend. The MACD of 0.26 indicates Negative momentum. The RSI at 59.13 is Neutral, neither overbought nor oversold. The STOCH value of 59.03 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:SECARE.
Swedencare AB Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
77 Outperform | kr12.37B | 37.27 | 24.35% | 1.95% | 8.83% | 7.11% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
59 Neutral | kr4.22B | 85.42 | 0.88% | 0.66% | 4.60% | -46.98% | |
52 Neutral | kr660.72M | -2.68 | ― | ― | -58.93% | -16.61% | |
52 Neutral | kr720.06M | -45.85 | -48.65% | ― | 79.13% | 55.77% | |
49 Neutral | kr674.80M | -14.25 | ― | ― | 9.56% | 19.12% | |
43 Neutral | kr27.82M | -0.43 | ― | ― | -86.56% | 8.75% |
* Consumer Defensive Sector Average
SE:SECARE
Swedencare AB
26.40
-15.91
-37.60%
SE:BIOG.B
BioGaia AB
122.30
21.68
21.55%
SE:ORX
Orexo AB
18.92
-0.86
-4.35%
SE:NANEXA
Nanexa AB
4.38
2.35
116.05%
SE:ENZY
Enzymatica AB
2.78
-0.29
-9.45%
SE:ERMA
Enorama Pharma AB
0.37
-1.80
-82.81%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.